Genmab Reports Promising Results for Epcoritamab in First-Line Lymphoma Trials

Reuters12-06 22:30

Genmab Reports Promising Results for Epcoritamab in First-Line Lymphoma Trials

Genmab A/S has announced updated results from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered T-cell engaging antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Data from the EPCORE NHL-2 trial showed overall response rates of 93% and 98% in two separate arms evaluating first-line, fixed-duration epcoritamab in combination with chemotherapies for newly diagnosed DLBCL. A third arm demonstrated a three-year overall survival rate of 96% in patients with FL following first-line combination treatment. Additionally, results from the EPCORE DLBCL-3 Phase 2 trial indicated encouraging overall and complete response rates for epcoritamab monotherapy in newly diagnosed, elderly patients with DLBCL and comorbidities. These results were presented at the 67th Annual Meeting and Exposition of the American Society of Hematology $(ASH)$.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001143391-en) on December 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589826983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-06 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589826983","market":"us","top_or_hot":-1,"title":"Genmab Reports Promising Results for Epcoritamab in First-Line Lymphoma Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Genmab Reports Promising Results for Epcoritamab in First-Line Lymphoma Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GMAB\">Genmab A/S</a> has announced updated results from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered T-cell engaging antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Data from the EPCORE NHL-2 trial showed overall response rates of 93% and 98% in two separate arms evaluating first-line, fixed-duration epcoritamab in combination with chemotherapies for newly diagnosed DLBCL. A third arm demonstrated a three-year overall survival rate of 96% in patients with FL following first-line combination treatment. Additionally, results from the EPCORE DLBCL-3 Phase 2 trial indicated encouraging overall and complete response rates for epcoritamab monotherapy in newly diagnosed, elderly patients with DLBCL and comorbidities. These results were presented at the 67th Annual Meeting and Exposition of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GNMSF\">Genmab A/S</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001143391-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genmab Reports Promising Results for Epcoritamab in First-Line Lymphoma Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenmab Reports Promising Results for Epcoritamab in First-Line Lymphoma Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-06 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Genmab Reports Promising Results for Epcoritamab in First-Line Lymphoma Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GMAB\">Genmab A/S</a> has announced updated results from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered T-cell engaging antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Data from the EPCORE NHL-2 trial showed overall response rates of 93% and 98% in two separate arms evaluating first-line, fixed-duration epcoritamab in combination with chemotherapies for newly diagnosed DLBCL. A third arm demonstrated a three-year overall survival rate of 96% in patients with FL following first-line combination treatment. Additionally, results from the EPCORE DLBCL-3 Phase 2 trial indicated encouraging overall and complete response rates for epcoritamab monotherapy in newly diagnosed, elderly patients with DLBCL and comorbidities. These results were presented at the 67th Annual Meeting and Exposition of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GNMSF\">Genmab A/S</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001143391-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014021.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL6vW4K:1","article_id":"2589826983","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589826983","pubTimestamp":1765031423,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Genmab A/S has announced updated results from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered T-cell engaging antibody, in adult patients with diffuse large B-cell lymphoma  and follicular lymphoma . Data from the EPCORE NHL-2 trial showed overall response rates of 93% and 98% in two separate arms evaluating first-line, fixed-duration epcoritamab in combination with chemotherapies for newly diagnosed DLBCL. A third arm demonstrated a three-year overall survival rate of 96% in patients with FL following first-line combination treatment. Additionally, results from the EPCORE DLBCL-3 Phase 2 trial indicated encouraging overall and complete response rates for epcoritamab monotherapy in newly diagnosed, elderly patients with DLBCL and comorbidities. These results were presented at the 67th Annual Meeting and Exposition of the American Society of Hematology .Disclaimer: This news brief was created by Public Technologies  using generative artificial","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Genmab报告Epcoritamab在一线淋巴瘤试验中取得有希望的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9},"content_text":"Genmab Reports Promising Results for Epcoritamab in First-Line Lymphoma Trials\n    \n\nGenmab A/S has announced updated results from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered T-cell engaging antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Data from the EPCORE NHL-2 trial showed overall response rates of 93% and 98% in two separate arms evaluating first-line, fixed-duration epcoritamab in combination with chemotherapies for newly diagnosed DLBCL. A third arm demonstrated a three-year overall survival rate of 96% in patients with FL following first-line combination treatment. Additionally, results from the EPCORE DLBCL-3 Phase 2 trial indicated encouraging overall and complete response rates for epcoritamab monotherapy in newly diagnosed, elderly patients with DLBCL and comorbidities. These results were presented at the 67th Annual Meeting and Exposition of the American Society of Hematology $(ASH)$.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001143391-en) on December 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589826983","isCrawlerRequest":true}